Bordoloi Biotech India Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -31.74%
- Profit Growth 83.52%
- Ebitda 83.53%
- Net Worth -6.45%
- Total Assets -1.51%
About Bordoloi Biotech India
Bordoloi Biotech India Private Limited (BBIPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 September 2016 (Eight years and four months 27 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Manash Baruah, Binoy Bordoloi, and Kulwant Saini serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999DL2016PTC306480
- Company No.
306480
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Sep 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Bordoloi Biotech India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Binoy Bordoloi  | Director | 27-Sep-2016 | Current |
Manash Baruah  | Director | 27-Sep-2016 | Current |
| Kulwant Saini | Director | 27-Sep-2016 | Current |
Financial Performance of Bordoloi Biotech India.
Bordoloi Biotech India Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 31.74% decrease. The company also saw a substantial improvement in profitability, with a 83.52% increase in profit. The company's net worth dipped by a decrease of 6.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bordoloi Biotech India?
In 2020, Bordoloi Biotech India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
H.D. Consortium India LimitedManash Baruah is a mutual person
Far N Beyond Sustainable LlpKulwant Saini is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bordoloi Biotech India?
Unlock and access historical data on people associated with Bordoloi Biotech India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bordoloi Biotech India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bordoloi Biotech India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.